Clinical trials: Cancer Head Neck
Head and Neck Neoplasms, Head and Neck Cancer
A Pilot Study to Evaluate the Feasibility and Potential Effectiveness of the Flexitouch System Head and Neck Treatment
The study will evaluate the feasibility and potential effectiveness of the Flexitouch head and neck treatment plus standard home care compared to standard home care regimen alone.
- Conditions
- Head and Neck Neoplasms, Head and Neck Cancer, Head and Neck Lymphedema
- Trial name
- NCT03332160
- Testing
- Flexitouch head and neck lymphedema treatment system, Standard home lymphedema care
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- Tactile Medical
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer
This is a feasibility study to assess the effectiveness of cetuximab when administered with low dose oral cyclophosphamide. Patients with metastatic squamous cell cancer of head and neck who have progressed on first line…
- Trial name
- NCT01581970
- Testing
- Cyclophosphamide, Cetuximab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Head and Neck Neoplasms
A Study for Patients With Head and Neck Cancer
This study will compare the effects of pemetrexed plus cisplatin versus cisplatin alone in head and neck cancer patients.
- Trial name
- NCT00415194
- Testing
- pemetrexed, cisplatin
- Where
- 94 sites in United States, Argentina and 19 more
- Volunteers
- 795 people
- Sponsor
- Eli Lilly and Company
Head and Neck Cancer
Surgery With or Without Adjuvant Stereotactic Body Radiotherapy
Comparison of patients with operable, recurrent previously-irradiated squamous cell head-and-neck cancers with or without adjuvant SBRT.
- Trial name
- NCT02516969
- Testing
- Stereotactic Body Radiotherapy
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- David A. Clump, MD, PhD
Oropharyngeal Squamous Cell Carcinoma (OPSCCA), HPV (Human Papillomavirus)-Associated
OPSCC N0 Nodal Control With Reduced IMRT
The dose of radiation most commonly used to treat oropharyngeal cancer results in side effects including sores in the mouth and throat, dry mouth and thick saliva, loss or altered taste, swallowing problems including pain or…
- Trial name
- NCT01891695
- Testing
- 39.6 Gy radiation
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Paul W. Read, MD
Head and Neck Cancer
The Use of Integra in Coverage of Radial Forearm Free Flap Donor Site Defect
The purpose of this research study is to compare the forearm free flap of patients with a traditional split thickness skin graft and those repaired with Integra (a skin substitute that helps to provide wound closure) and a split…
- Trial name
- NCT02980601
- Testing
- Integra plus STSG, STSG
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Wake Forest University Health Sciences
Head and Neck Cancer, Oral Mucositis
Commensal Oral Microbiota in Head and Neck Cancer
The ARMOR Trial will test the efficacy of an oral care protocol to treat oral mucositis (OM) in patients receiving radiation (RT) or chemoradiation (chemoRT) for head and neck cancer.
- Trial name
- ARMOR (NCT03843554)
- Testing
- Standard of Care Oral Hygiene, Oral mucosal deterging and dental prophylaxis
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Pennsylvania
Nausea and Vomiting, Stage III Squamous Cell Carcinoma of the Hypopharynx
Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy
RATIONALE: Fosaprepitant dimeglumine, palonosetron hydrochloride, and dexamethasone may help lessen or prevent nausea and vomiting caused by cisplatin in patients with head and neck cancer undergoing chemotherapy and radiation…
- Conditions
- Nausea and Vomiting, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity
- Trial name
- NCT00895245
- Testing
- fosaprepitant dimeglumine, cisplatin, palonosetron hydrochloride
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Washington
Head and Neck Cancer
Central Pain Syndrome in Survivors of Head and Neck Cancer
This is a cross-sectional pilot study of head and neck cancer survivors who have completed multi-modal treatment to assess and characterize the presence of distinct pain syndromes.
- Trial name
- NCT04128267
- Testing
- IPC-1000, Magnetic resonance imaging, Correlative Studies
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Vanderbilt-Ingram Cancer Center
Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
The goal of this study is to learn if giving cemiplimab and vidutolimod together could be effective in treating advanced cancer.
- Conditions
- Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- NCT04916002
- Testing
- vidutolimod, cemiplimab
- Where
- 24 sites in United States, Australia
- Volunteers
- 77 people
- Sponsor
- Regeneron Pharmaceuticals
Oropharynx Squamous Cell Carcinoma
Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer
The purpose of this study is to find out if the addition of nivolumab can improve 2 year progression free survival (PFS) as compared to standard of care of fractionated radiation therapy (RT) and carboplatin/paclitaxel in…
- Trial name
- NCT03829722
- Testing
- Nivolumab, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Michigan Rogel Cancer Center
Squamous Cell Carcinoma of the Head and Neck
A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)
This is a Phase Ib/II, open-label, multicenter, randomized, umbrella study in participants with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
- Trial name
- NCT05459129
- Testing
- Atezolizumab, Tiragolumab, Carboplatin
- Where
- 6 sites in United States, Israel and 1 more
- Volunteers
- 12 people
- Sponsor
- Hoffmann-La Roche
Esophageal Cancer
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
This is an open-label, Phase 1/2 study to evaluate the safety of durvalumab (MEDI4736) in combination with oxaliplatin/capecitabine chemotherapy in metastatic/locally advanced oesophageal cancer (OC) and with neoadjuvant…
- Trial name
- NCT02735239
- Testing
- Durvalumab, Tremelimumab, Oxaliplatin
- Where
- 4 sites in United Kingdom
- Volunteers
- 73 people
- Sponsor
- Ludwig Institute for Cancer Research
Recurrent Oral Cavity Adenoid Cystic Carcinoma, Recurrent Salivary Gland Carcinoma
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
This phase II trial studies how well Akt inhibitor MK2206 works in treating patients with progressive, recurrent, or metastatic adenoid cyst carcinoma (cancer).
- Conditions
- Recurrent Oral Cavity Adenoid Cystic Carcinoma, Recurrent Salivary Gland Carcinoma, Salivary Gland Adenoid Cystic Carcinoma, Stage IVA Major Salivary Gland Cancer AJCC v7
- Trial name
- NCT01604772
- Testing
- Akt Inhibitor MK2206, Laboratory Biomarker Analysis
- Where
- 51 sites in United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Squamous Cell Carcinoma (ESCC)
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
The purpose of this study is to evaluate the efficacy and safety of tislelizumab as first line treatment in combination with chemotherapy in participants with advanced unresectable/metastatic esophageal squamous cell carcinoma…
- Trial name
- NCT03783442
- Testing
- Cisplatin, Oxaliplatin, Fluorouracil (5-FU)
- Where
- 124 sites in United States, Australia and 14 more
- Volunteers
- 649 people
- Sponsor
- BeiGene
Neoplasms, Oral, Mouth Neoplasms
GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer
This phase II trial studies how trametinib effects tumor cells in patients with oral cavity squamous cell carcinoma that can be removed by surgery.
- Trial name
- NCT01553851
- Testing
- GSK1120212
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Head and Neck Cancer
RAD001, Cisplatin and Concurrent Radiation for Locally Advanced, Inoperable Head and Neck Cancer
The purpose of this study is to determine if RAD001, to a maximum dose of 10 mg/day, can be safely administered with cisplatin, and concurrent radiotherapy, for patients with locally advanced, inoperable, squamous cell carcinoma…
- Trial name
- NCT01057277
- Testing
- RAD001(Afinitor)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- howard safran
Head and Neck Cancer
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as E7389, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00337129
- Testing
- eribulin mesylate
- Where
- 139 sites in United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Squamous Cell Carcinomas
The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer
This trial aims to directly compare a reduced radiation dose to the standard of care in HPVOPC for non-inferiority, thus allowing for direct comparison of outcomes between the two groups.
- Trial name
- NCT01706939
- Testing
- Reduced Dose Radiation, Standard Dose Radiation, Carboplatin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Carcinoma, Squamous Cell of Head and Neck
PD 0332991 and Cetuximab in Patients With Incurable SCCHN
The purpose of this Phase I/II study is to define the maximum tolerated dose of PD 0332991 given with cetuximab and evaluated the side effects of the combination.
- Trial name
- NCT02101034
- Testing
- Cetuximab, PD 0332991
- Where
- 5 sites in United States
- Volunteers
- 96 people
- Sponsor
- Washington University School of Medicine